AUTHOR=Zhang Yiyuan , Chen Yanxing 

TITLE=Stratification From Heterogeneity of the Cell-Death Signal Enables Prognosis Prediction and Immune Microenvironment Characterization in Esophageal Squamous Cell Carcinoma

JOURNAL=Frontiers in Cell and Developmental Biology

VOLUME=Volume 10 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2022.855404

DOI=10.3389/fcell.2022.855404

ISSN=2296-634X

ABSTRACT=Esophageal squamous cell carcinoma (ESCC) is the primary subtype of esophageal cancer (EC) characterized by high incidence rate and extremely poor prognosis worldwide. Previous studies suggested the specific cell death signal linked to the different immune subtypes in multiple cancers, while a comprehensive investigation in ESCC is yet to be performed, and the later had a low response rate of immunotherapy. In the current study, we dissected different cell death signals in ESCC tumors and then integrated that functional information to stratify ESCC patients into different immunogenic cell death (ICD) subtypes. By systematically analyzing the transcriptomes of 857 patients and proteomic profile of 124 patients, we found that the signals of necroptosis, pyroptosis and ferroptosis are positively associated with activated immunity in ESCC. We identified two ICD pattern terms ICD-high and ICD-low subtypes that positively correlated to both progression-free survival (p =0.03) and overall survival(p=0.01). In addition, cell fraction deconvolution analysis revealed more infiltrated leukocytes were enriched in ICD-high types, especially antigen presenting cells, such as dendritic cells and macrophages. With the XGBoost algorithm, we further developed a 14-gene signature which can simplify the subtyping for allocating new samples, by which we validated the prognosis value of the signature and proved that the ICD score scheme could serve as a promising biomarker for stratifying patients with immunotherapy in several immune checkpoint blockade treatment cohorts. Collectively, we successfully constructed the ICD scheme enables predicting the prognosis or immunotherapy efficacy in ESCC patients and uncovered the critical interplay between cell death signals and immune status in ESCC.